Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| CDXS | CODEXIS, INC. | 2026-04-02 18:59:53 | 1.78 | -0.04 | -2.2 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDXS | 0001200375 | CODEXIS, INC. | US1920051067 | 549300KGLM6CDPTVSE20 | 710872999 | Nasdaq | 2860 | Industrial Organic Chemicals | 1231 | DE | 200 PENOBSCOT DRIVE | REDWOOD CITY | CA | 94063 | UNITED STATES | US | 650-421-8100 | 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063 | 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063 | CODEXIS INC | Protein engineering | 2002 | Stephen Dilly, Ph.D. | 165 | http://codexis.com | 133,400,000 | 90,478,000 | 90,869,349 | Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications. | 2026-04-02 19:05:01 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 133,400,000 | -19,000,000 | -12.4672 | 90,869,349 | 8,032,038 | 9.6962 |
| 2024 | 152,400,000 | 30,000,000 | 24.5098 | 82,837,311 | 12,533,672 | 17.8279 |
| 2023 | 122,400,000 | -261,400,000 | -68.1084 | 70,303,639 | 4,356,832 | 6.6066 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Kevin Norrett | Chief Operating Officer | 2024 | 474,485 | 0 | 159,668 | 237,242 | 14,840 | 1,518,851 |
| Alison Moore | Chief Technical Officer, Executive Vice President | 2024 | 115,382 | 0 | 248,498 | 57,691 | 71,586 | 1,102,937 |
| Stephen Dilly | Chief Executive Officer, Director, President, Chairman Of The Board | 2024 | 713,550 | 0 | 437,446 | 535,163 | 53,800 | 3,472,920 |
| Georgia Erbez | Chief Financial Officer | 2024 | 115,382 | 0 | 148,500 | 57,691 | 240 | 931,593 |
| Sriram Ryali | Chief Financial Officer | 2024 | 354,202 | 0 | 159,668 | 173,812 | 163,379 | 1,483,677 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 146 |
| 2024 | 188 |
| 2023 | 174 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 70,387,000 | 59,345,000 | 70,143,000 |
| Cost Of Revenue | 9,338,000 | 16,288,000 | 12,809,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 52,307,000 | 46,263,000 | 58,885,000 |
| General And Administrative Expenses | 47,074,000 | 55,148,000 | 53,250,000 |
| Operating Expenses | 112,126,000 | 117,864,000 | 138,212,000 |
| Operating Income | -41,739,000 | -58,519,000 | -68,069,000 |
| Net Income | -43,974,000 | -65,276,000 | -76,240,000 |
| Earnings Per Share Basic | -0.5 | -0.89 | -1.12 |
| Earnings Per Share Diluted | -0.5 | -0.89 | -1.12 |
| Weighted Average Shares Outstanding Basic | 87,142,000 | 73,408,000 | 68,131,000 |
| Weighted Average Shares Outstanding Diluted | 87,142,000 | 73,408,000 | 68,131,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 50,793,000 | 19,264,000 | 65,116,000 |
| Marketable Securities Current | 27,416,000 | 54,194,000 | — |
| Accounts Receivable | 492,000 | 4,375,000 | 10,036,000 |
| Inventories | 1,817,000 | 1,799,000 | 2,685,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 500,000 | 500,000 | 600,000 |
| Total Assets Current | 96,816,000 | 98,772,000 | 93,466,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 13,024,000 | 14,197,000 | 15,487,000 |
| Other Assets Non Current | 883,000 | 1,019,000 | 1,246,000 |
| Total Assets Non Current | 43,575,000 | 43,098,000 | 28,624,000 |
| Total Assets | 147,797,000 | 149,011,000 | 136,561,000 |
| Accounts Payable | 1,554,000 | 2,838,000 | 5,947,000 |
| Deferred Revenue | 7,009,000 | 350,000 | 3,781,000 |
| Short Term Debt | 0 | 0 | — |
| Other Liabilities Current | 2,768,000 | 6,223,000 | 4,735,000 |
| Total Liabilities Current | 25,317,000 | 23,648,000 | 35,830,000 |
| Long Term Debt | 40,105,000 | 28,905,000 | — |
| Other Liabilities Non Current | 1,327,000 | 1,268,000 | 1,233,000 |
| Total Liabilities Non Current | 71,951,000 | 58,436,000 | 14,116,000 |
| Total Liabilities | 97,268,000 | 82,084,000 | 49,946,000 |
| Common Stock | 9,000 | 8,000 | 7,000 |
| Retained Earnings | -606,780,000 | -562,806,000 | -497,530,000 |
| Accumulated Other Comprehensive Income | 8,000 | 52,000 | — |
| Total Shareholders Equity | 50,529,000 | 66,927,000 | 86,615,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 5,248,000 | 4,946,000 | 5,518,000 |
| Share Based Compensation Expense | 9,624,000 | 13,087,000 | 9,971,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | 19,000 | -886,000 | 656,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -1,286,000 | -2,567,000 | 2,287,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -19,376,000 | -49,410,000 | -52,638,000 |
| Purchases Of Marketable Securities | 57,158,000 | 90,235,000 | — |
| Sales Of Marketable Securities | 0 | 1,973,000 | — |
| Acquisition Of Property Plant And Equipment | 4,471,000 | 4,305,000 | 4,418,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 23,502,000 | -56,980,000 | -4,858,000 |
| Tax Withholding For Share Based Compensation | 0 | 0 | 404,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 17,267,000 | 31,319,000 | 8,652,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 9,897,000 | 29,521,000 | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 27,928,000 | 60,522,000 | 8,167,000 |
| Change In Cash | 32,054,000 | -45,868,000 | -49,329,000 |
| Cash At End Of Period | 50,793,000 | 19,264,000 | 65,116,000 |
| Income Taxes Paid | 0 | 17,000 | 194,000 |
| Interest Paid | 3,149,000 | 2,566,000 | 44,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.5 | -0.89 | -1.12 |
| Price To Earnings Ratio | -3.26 | -5.3596 | -2.7232 |
| Earnings Growth Rate | -43.8202 | -20.5357 | 119.6078 |
| Price Earnings To Growth Ratio | 0.0744 | 0.261 | -0.0228 |
| Book Value Per Share | 0.5798 | 0.9117 | 1.2713 |
| Price To Book Ratio | 2.8111 | 5.2319 | 2.3991 |
| Ebitda | -34,226,000 | -56,813,000 | -70,528,000 |
| Enterprise Value | 131,353,460 | 359,797,160 | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.7937 | 0.4319 | — |
| Capital Expenditures | 4,075,000 | 3,656,000 | -1,609,000 |
| Free Cash Flow | -23,451,000 | -53,066,000 | -51,029,000 |
| Return On Equity | -0.8703 | -0.9753 | -0.8802 |
| One Year Beta | 1.9239 | 1.9877 | 2.6812 |
| Three Year Beta | 2.1132 | 2.0583 | 2.0334 |
| Five Year Beta | 1.996 | 1.556 | 1.5197 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Lutz Stefan | Chief Scientific Officer | 2026-02-24 | 5,862 | D | 130,421 |
| Erbez Georgia | — | 2026-02-23 | 316,100 | A | 316,100 |
| MOORE ALISON | Director, President and CEO | 2026-02-23 | 993,000 | A | 993,000 |
| Lutz Stefan | Chief Scientific Officer | 2026-02-23 | 316,100 | A | 316,100 |
| MOORE ALISON | Director, President and CEO | 2026-02-06 | 3,826 | D | 250,506 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Lamar Smith | 2018-05-08 | TX21 | Purchase | 2018-04-06 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 1,170,518 | 718,109 | 1.63 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 1,630 | 1,000 | 1.63 |
| Caitong International Asset Management Co., Ltd | 2025-12-31 | 49,534 | 30,389 | 1.63 |
| Sunbelt Securities, Inc. | 2025-12-31 | 49 | 30 | 1.6333 |
| Invesco Ltd. | 2025-12-31 | 284,581 | 174,590 | 1.63 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Global X Funds | 2026-01-31 | Global X Russell 2000 ETF | RSSL | 40,288 | 49,957.12 | 0.0036 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 110,823 | 137,420.52 | 0.0051 |
| VANGUARD EXPLORER FUND | 2026-01-31 | Admiral Shares | VEXRX | 237,927 | 295,029.48 | 0.0014 |
| VANGUARD EXPLORER FUND | 2026-01-31 | Investor Shares | VEXPX | 237,927 | 295,029.48 | 0.0014 |
| ProFunds | 2026-01-31 | SMALL-CAP PROFUND SERVICE CLASS | SLPSX | 93 | 115.32 | 0.0015 |